Crystal Tuncay, DO
Internal Medicine · Valparaiso, INNPI 1992790414
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 59.4% of the total. Reporting peaked in 2021 at $15,066 and has fallen 86.1% since, to $2,101 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 913 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Amgen$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$665
- Boehringer Ingelheim$575
- plus $7K from 54 others
What the payments were for
- Speaking & faculty fees$16,52550%
- Travel & lodging$6872%
- Food & beverage$15,61347%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,947 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $133,659 |
| FarxigaDapagliflozin Propanediol | 96 | $92,782 |
| JardianceEmpagliflozin | 45 | $55,293 |
| JanuviaSitagliptin Phosphate | 36 | $53,263 |
| TrulicityDulaglutide | 29 | $48,975 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $42,339 |
| Repatha SureclickEvolocumab | 33 | $35,231 |
| VascepaIcosapent Ethyl | 43 | $27,741 |
| MounjaroTirzepatide | 22 | $26,223 |
| RybelsusSemaglutide | 15 | $19,741 |
| WegovySemaglutide | 13 | $17,019 |
| EntrestoSacubitril/Valsartan | 17 | $16,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $14,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $12,662 |
| MyrbetriqMirabegron | 15 | $12,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,241 | $170,420118 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,730 | $105,443112 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $665 | $75,19751 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $575 | $61,53657 claims |
| MerckJanuvia | $447 | $53,26336 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $236 | $27,23338 claims |
| NovartisEntresto | $331 | $16,62817 claims |
| AbbVieLinzess, Synthroid | $19,567 | $16,51772 claims |
| Astellas Pharma US IncMyrbetriq | $517 | $12,64315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $2,864321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Valparaiso
- Hector MarchandValparaiso$16K
- Robert BuynakValparaiso$15K
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.